COMPASS

Rivaroxaban with or without aspirin in stable cardiovascular disease - The New England Journal of Medicine - 2017

Brief Summary:

In patients with established stable atherosclerotic disease, rivaroxaban plus aspirin resulted in a modest 1.3% absolute risk reduction in cardiovascular death, stroke, or nonfatal MI, with a trend toward improved mortality. This benefit was offset by a 1.2% increased absolute risk in major bleeding.

Reference: http://www.ncbi.nlm.nih.gov/pubmed/28844192